HIMS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Hims & Hers Health (HIMS) is not a clear buy right now for a Beginner focused on long-term investing, even with $50,000-$100,000 available. The stock has positive momentum and strong hedge-fund accumulation, but the current setup is mixed: price is near resistance, analyst views are split, and the business still depends heavily on proving its GLP-1/peptide growth story. For an impatient investor, I would not call this a strong buy today. I would hold and wait for either a cleaner breakout above resistance with confirming follow-through or a better risk/reward entry.
HIMS closed at 37.05 after a modest daily gain from 36.8, but the broader setup is still mixed. MACD histogram is positive and expanding, which supports bullish momentum. However, RSI_6 at 71.991 suggests the stock is getting stretched in the short term. Moving averages are converging, which usually signals an indecisive trend rather than a clean long-term entry. Key levels: pivot 34.388, resistance 1 at 37.525, resistance 2 at 39.462, support 1 at 31.252. Price is currently pressing into the first resistance zone, so upside is possible, but the current spot is not an ideal beginner entry for a long-term position.
Recent catalysts are supportive overall. Hims secured a $400 million financing agreement with JPMorgan Chase, which improves liquidity and supports healthcare and pharmacy operations. Analysts at Canaccord, Barclays, JPMorgan, and Needham have recently raised targets or maintained bullish ratings, citing improving card-data trends, early traction in branded GLP-1, and growing enthusiasm around peptides. Hedge funds are also buying aggressively, with buying up 211.82% over the last quarter.
The main negatives are execution and regulatory uncertainty. The FDA declined to propose seven peptides for the bulk compounding list, which may limit product diversity and the company’s competitive flexibility. Analysts also note it is still too early to know whether Hims can retain enough GLP-1 subscribers to justify the EBITDA ramp in guidance. Earlier quarter results were mixed, with missed revenue and EBITDA expectations and lowered FY26 EBITDA guidance. The stock is also trading close to resistance after a strong recent run, which reduces the appeal for an impatient buyer.
No latest-quarter financial snapshot was provided because the financial snapshot data returned an error. Based on the analyst commentary, the latest reported quarter was mixed: revenue and adjusted EBITDA came in below expectations, and FY26 EBITDA guidance was cut. The most recent discussion suggests growth is being driven by weight-loss and other moderate contributors, but profitability and subscriber retention still need to prove out. Latest quarter season: Q1 2026.
Analyst sentiment has improved recently, but it is still mixed. Positive: Canaccord raised its target to $40 and keeps Buy; Barclays raised to $39 and keeps Overweight; JPMorgan raised to $33 and stays Overweight; Needham raised to $35 and keeps Buy. Negative/neutral: BofA lowered its target multiple earlier, then recently raised target to $36 but kept Neutral, and Jefferies remains Hold with a much lower target of $24.50. Wall Street pros: bulls see accelerating revenue/EBITDA and GLP-1/peptide upside; bears focus on execution risk, margin pressure, and uncertainty around retaining subscribers and achieving the expected second-half ramp.
